iBio, Inc. Common Stock (IBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, iBio, Inc. Common Stock (IBIO) has a cash flow conversion efficiency ratio of -0.073x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.23 Million) by net assets ($85.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see iBio, Inc. Common Stock (IBIO) market capitalisation for the company's overall valuation and market capitalisation.
iBio, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2007–2026)
This chart illustrates how iBio, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
iBio, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of iBio, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore IBIO cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Min Aik Precision Industrial Co Ltd
TW:4545
|
-0.051x |
|
Scully Royalty Ltd
F:MB01
|
0.026x |
|
Holland Colours NV
AS:HOLCO
|
-0.010x |
|
Kalleback Property Invest AB
ST:KAPIAB
|
0.049x |
|
Outcrop Gold Corp
V:OCG
|
-0.200x |
|
U-Best Polymer Industry Co Ltd
TWO:4714
|
-0.026x |
|
Air T Inc
NASDAQ:AIRT
|
-0.034x |
|
Ratchaphruek Hospital Public Company Limited
BK:RPH
|
0.046x |
Annual Cash Flow Conversion Efficiency for iBio, Inc. Common Stock (2007–2026)
The table below shows the annual cash flow conversion efficiency of iBio, Inc. Common Stock from 2007 to 2026. View latest iBio, Inc. Common Stock stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $85.71 Million | $-23.22 Million | -0.271x | +73.66% |
| 2025-06-30 | $14.88 Million | $-15.30 Million | -1.028x | -18.20% |
| 2024-06-30 | $21.32 Million | $-18.55 Million | -0.870x | +56.03% |
| 2023-06-30 | $15.38 Million | $-30.44 Million | -1.979x | -232.32% |
| 2022-06-30 | $63.48 Million | $-37.80 Million | -0.595x | -115.03% |
| 2021-06-30 | $108.57 Million | $-30.06 Million | -0.277x | -17.46% |
| 2020-06-30 | $56.61 Million | $-13.35 Million | -0.236x | +95.86% |
| 2019-06-30 | $2.46 Million | $-13.97 Million | -5.688x | -582.03% |
| 2018-06-30 | $16.16 Million | $-13.48 Million | -0.834x | +43.52% |
| 2017-06-30 | $8.91 Million | $-13.16 Million | -1.477x | -339.80% |
| 2016-06-30 | $24.04 Million | $-8.07 Million | -0.336x | +20.20% |
| 2015-06-30 | $11.23 Million | $-4.72 Million | -0.421x | +37.66% |
| 2014-06-30 | $6.10 Million | $-4.12 Million | -0.675x | +29.47% |
| 2013-06-30 | $5.07 Million | $-4.85 Million | -0.957x | +1.78% |
| 2012-06-30 | $6.17 Million | $-6.01 Million | -0.974x | +96.41% |
| 2011-06-30 | $196.64K | $-5.34 Million | -27.147x | -1144.06% |
| 2010-06-30 | $1.08 Million | $-2.35 Million | -2.182x | -372.91% |
| 2009-06-30 | $4.39 Million | $-2.02 Million | -0.461x | -348.99% |
| 2008-06-30 | $-6.20 Million | $-1.15 Million | 0.185x | -5.46% |
| 2007-06-30 | $-4.33 Million | $-849.38K | 0.196x | -- |
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu,… Read more